| ▲ | dgacmu 12 minutes ago | |
It sucks less than existing chemo: > Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group. That's a huge reduction in side effects bad enough to stop treatment. | ||